
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) …